Carmignac Portfolio Grandchildren: Letter from the Fund Managers
Over the second quarter, Carmignac Portfolio Grandchildren posted a positive performance of +2.15%, underperforming its reference indicator (+3.42%). This brought the fund performance for the year to date to +17.94%, versus +15.18% for the reference indicator.
Market environment
The second quarter continued the positive trend of the first quarter with equity markets delivering positive returns despite some volatility. Monetary policy risk has gradually been replaced by political risk, which has led to dispersion across regions and sectors. Leadership among stocks and sectors constantly changed over the period and this was reflected in Energy and Financials as well as Healthcare and Technology being among the better performing sectors. Overall, the US markets outperformed, benefiting from the strong earnings of technology companies. Meanwhile, Europe faced political instability in June due to an unforeseen snap election called by Macron, which had a detrimental effect on the overall returns in the region.
How did we fare in this context?
The fund's largest exposure remains in the technology sector, which also performed exceptionally well in the second quarter. Nvidia's impressive performance continued, with a 39% increase in the quarter, driven by strong and widespread demand for GPUs from major hyperscalers, enterprises, and sovereigns. This demand-supply balance is expected to remain tight for the rest of the year. The positive news flow in the semiconductor sector is evident through the performance of companies like ASML (+8%). However, towards the end of the quarter, we significantly reduced our holding in Nvidia, from an average weighting of around 5% to just 2% by the end of June. This decision was influenced by the stock's substantial 150% rise in 2024 alone, placing it at the higher end of its valuation range at approximately 50 times the estimated earnings for 2025. As a result, we decided to take some profits with a view to adding back on momentum reversal.
Our more defensive stocks also demonstrated strong performance throughout the quarter, particularly in the Consumer Staples and Healthcare sectors. Notably, Colgate experienced a 9% increase, following another quarter of better-than-anticipated results. Similarly, Novo Nordisk witnessed a 14% surge in value, driven not only by a robust financial report but also by the significant expansion of their supply for the previously limited obesity drug, Wegovy. This expansion was prompted by an overwhelming demand for the product.
However, there were also some disappointing performances in the consumer and healthcare sectors during the quarter. Estee Lauder, for example, experienced a significant decline of 29% in the quarter due to negative reaction to their quarterly results. Although the company confirmed a positive growth of 6% organic in their fiscal 3rd quarter to March, with expectations of further acceleration towards the end of the year as the over-stocking issue in Asian travel retail had been resolved, their full-year guidance fell slightly below expectations. This, combined with a lacklustre global consumer backdrop, triggered a sell-off. Healthcare companies with consumer exposure, such as Align Technology, specializing in orthodontics, and Demant, known for hearing aids, were also adversely affected by concerns about global consumer strength. As a result, their stocks plummeted by 25% and 12% respectively, even though there is currently no concrete evidence of any significant impact on their financial results.
Outlook
Our macro overlay framework continues to indicate a defensive stance towards equity markets. In line with our cautious macroeconomic outlook, we have taken further steps to reduce exposure to economically sensitive stocks. During the second quarter, this involved reducing positions in high-valued software companies such as Palo Alto, ServiceNow, Salesforce, Intuit, Adobe, as well as AMD, Amadeus, TransUnion, and others. On the other hand, we have increased our holdings in consumer staples and healthcare stocks, particularly those we believe have been unfairly undervalued.
One notable addition to our portfolio is Vertex Pharma, a healthcare company that stood out in our screening process. This change represents the largest adjustment we have made. Vertex Pharma is one of the few large pharmaceutical stocks that performed well in our evaluation. Additionally, the company currently presents an attractive opportunity. It holds a strong position as a provider of drugs for cystic fibrosis (treatment, and we anticipate the approval of their next-generation drug later this year. Furthermore, Vertex Pharma has promising prospects in other therapeutic areas, including pain treatment and kidney disease.
Carmignac Portfolio Grandchildren
An intergenerational Fund focused on quality, sustainable companiesDiscover the fund pageCarmignac Portfolio Grandchildren A EUR Acc
- Recommended minimum investment horizon
- 5 years
- Risk indicator*
- 4/7
- SFDR - Fund Classification**
- Article 9
*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
Main risks of the fund
Fees
- Entry costs
- 4,00% of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of the actual charge.
- Exit costs
- We do not charge an exit fee for this product.
- Management fees and other administrative or operating costs
- 1,70% of the value of your investment per year. This estimate is based on actual costs over the past year.
- Performance fees
- 20,00% when the share class overperforms the Reference indicator during the performance period. It will be payable also in case the share class has overperformed the reference indicator but had a negative performance. Underperformance is clawed back for 5 years. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
- Transaction Cost
- 0,26% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.
Performance
| Carmignac Portfolio Grandchildren | 15.5 | 20.3 | 28.4 | -24.2 | 23.0 |
| Reference Indicator | 15.5 | 6.3 | 31.1 | -12.8 | 19.6 |
| Carmignac Portfolio Grandchildren | + 6.0 % | + 12.5 % | + 14.0 % |
| Reference Indicator | + 11.1 % | + 13.4 % | + 14.8 % |
Source: Carmignac at Nov 29, 2024.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Related articles
Carmignac Portfolio Grandchildren: Reinvesting to reinvent ourselves
![[Background image] [CI] Blue sky and buildings](https://carmignac.imgix.net/uploads/article/0001/05/CI_WEB.jpg?auto=format%2Ccompress&fit=fill&w=3840)
35 years in the global equity arena, many more ahead
Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.
This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.
The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.
In France, Luxembourg, Sweden: The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds’ prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management.
In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.
In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.
The Management Company can cease promotion in your country anytime.
Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden.